![](/wp-content/uploads/2022/10/October-27-2022-Blast-Cover.png)
$599
Teladoc, Alnylam, and Amarin Q3 ’22 Earnings Updates
A series of cardiometabolic-related news items have been observed: Teladoc (press release; slides), Alnylam (press release; slides), and Amarin (press release; slides) hosted their Q3 ’22 earnings calls. Below, FENIX provides highlights and insights for the respective new items.